Biomedicines,
Journal Year:
2023,
Volume and Issue:
11(3), P. 890 - 890
Published: March 14, 2023
Despite
recent
therapeutic
advances,
pancreatic
ductal
adenocarcinoma
(PDAC)
remains
one
of
the
most
aggressive
malignancies,
with
remarkable
resistance
to
treatment,
poor
prognosis,
and
clinical
outcome.
More
efficient
approaches
are
urgently
needed
improve
patients’
survival.
Recently,
development
organoid
culture
systems
has
gained
substantial
attention
as
an
emerging
preclinical
research
model.
PDAC
organoids
have
been
developed
study
cancer
biology,
progression,
treatment
response,
filling
translational
gap
between
in
vitro
vivo
models.
Here,
we
review
rapidly
evolving
field
their
potential
powerful
tools
that
could
pave
way
towards
precision
medicine
for
cancer.
Cancer Research Communications,
Journal Year:
2024,
Volume and Issue:
4(4), P. 970 - 985
Published: March 22, 2024
Abstract
Immunotherapies
for
cancers
of
epithelial
origin
have
limited
efficacy,
and
a
growing
body
evidence
links
the
composition
extracellular
matrix
(ECM)
with
likelihood
favorable
response
to
treatment.
The
ECM
may
be
considered
an
immunologic
barrier,
restricting
localization
cytotoxic
immune
cells
stromal
areas
inhibiting
their
contact
tumor
cells.
Identifying
components
this
barrier
could
provide
targets
that
whether
degraded
in
situ
support
antitumor
immunity
improve
immunotherapy
response.
Using
library
primary
triple-negative
breast
cancer
tissues,
we
correlated
CD8+
T-cell
identified
proteoglycan,
versican
(VCAN),
as
putative
member
barrier.
Our
analysis
reveals
associates
location
VCAN
expression,
specific
glycovariant
[defined
through
pattern
posttranslational
attachments
glycosaminoglycans
(GAG)],
cell
types
produce
variant.
In
functional
studies,
isomers
chondroitin
sulfate
presented
on
opposing
roles
being
either
supportive
or
trafficking,
removal
GAGs
ameliorates
these
effects
trafficking.
Overall,
conclude
can
inhibit
trafficking
within
microenvironment
depending
present,
is
major
component
defines
type
immunotherapy.
Significance:
has
been
poor
toward
solid
tumors
despite
infiltrating
into
tumor.
associated
impacting
infiltration
article
its
structural
modification,
having
key
role
invasion.
Nature Communications,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: Jan. 27, 2024
Animal
studies
have
demonstrated
the
ability
of
pancreatic
acinar
cells
to
transform
into
ductal
adenocarcinoma
(PDAC).
However,
tumorigenic
potential
human
remains
under
debate.
To
address
this
gap
in
knowledge,
we
expand
sorted
as
3D
organoids
and
genetically
modify
them
through
introduction
common
PDAC
mutations.
The
undergo
dramatic
transcriptional
alterations
but
maintain
a
recognizable
DNA
methylation
signature.
transcriptomes
are
similar
those
disease-specific
cell
populations.
Oncogenic
KRAS
alone
do
not
organoids.
can
form
vivo
after
acquiring
four
most
driver
mutations
disease.
Similarly,
carrying
these
genetic
also
PDAC,
thus
experimentally
proving
that
PDACs
originate
from
both
cells.
RNA-seq
analysis
reveal
shift
normal
towards
with
enhanced
proliferation,
metabolic
rewiring,
down-regulation
MHC
molecules,
coagulation
complement
cascade.
By
comparing
PDAC-like
pancreas
samples,
identify
group
genes
elevated
expression
during
early
transformation
which
represent
diagnostic
biomarkers.
Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
13(21)
Published: Feb. 15, 2024
Patient-derived
organoids
(PDOs)
developed
ex
vivo
and
in
vitro
are
increasingly
used
for
therapeutic
screening.
They
provide
a
more
physiologically
relevant
model
drug
discovery
development
compared
to
traditional
cell
lines.
However,
several
challenges
remain
be
addressed
fully
realize
the
potential
of
PDOs
This
paper
summarizes
recent
advancements
PDO
enhancement
culture
models.
is
achieved
by
leveraging
materials
engineering
microfabrication
technologies,
including
organs-on-a-chip
droplet
microfluidics.
Additionally,
this
work
discusses
application
therapy
screening
meet
diverse
requirements
overcome
bottlenecks
cancer
treatment.
Furthermore,
introduces
tools
data
processing
analysis
organoids,
along
with
their
microenvironment.
These
aim
achieve
enhanced
readouts.
Finally,
explores
future
perspectives
using
personalized
patients.
Biomedicines,
Journal Year:
2023,
Volume and Issue:
11(3), P. 890 - 890
Published: March 14, 2023
Despite
recent
therapeutic
advances,
pancreatic
ductal
adenocarcinoma
(PDAC)
remains
one
of
the
most
aggressive
malignancies,
with
remarkable
resistance
to
treatment,
poor
prognosis,
and
clinical
outcome.
More
efficient
approaches
are
urgently
needed
improve
patients’
survival.
Recently,
development
organoid
culture
systems
has
gained
substantial
attention
as
an
emerging
preclinical
research
model.
PDAC
organoids
have
been
developed
study
cancer
biology,
progression,
treatment
response,
filling
translational
gap
between
in
vitro
vivo
models.
Here,
we
review
rapidly
evolving
field
their
potential
powerful
tools
that
could
pave
way
towards
precision
medicine
for
cancer.
